Switzerland· 63097002

Iclusig

A ponatinib product containing ponatinibum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01EA05

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedIclusigATCL01EA05REGISTER NO.63097002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Ponatinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L01EA05 (ponatinib), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Ponatinib · ATC L01EA05

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ponatinib costs, country by country.

Normalised to the WHO defined daily dose (45 mg), so markets compare like for like.

  • Switzerland: $296.54 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Ponatinib · price per daily dose (45 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$296.54
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
ponatinibum
Manufacturer
—
Country
Switzerland (CH)
ATC code
L01EA05
ATC class
Ponatinib
Defined daily dose
45 mg, O
Swissmedic category
A
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680630970022
    Fl 30 Stk
    CHF 5288.2

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

500 interactions on record for ponatinib.

Graded by severity as the source publishes them — 166 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ponatinib · interactions on record

500 records

  • 166 severe
  • 303 moderate
  • 31 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0932c6fa-e8ee-4e87-8666-c2bd61527aa9
GET /v1/drugs/0932c6fa-e8ee-4e87-8666-c2bd61527aa9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "ponatinibum 45 mg",
  "valid_from": "2023-03-01",
  "limitations": "[{\"description\":\"ICLUSIG wird vergütet bei erwachsenen Patienten mit<br>\\n<br>\\n-\\tPhiladelphia-Chromosom-positiver (Ph+) chronischer myeloischer Leukämie (in der chronischen Phase, akzelerierten Phase oder Blastenkrise), bei denen eine T315I-Mutation vorliegt, oder Ph+ akuter Lymphoblastenleukämie, bei denen eine T315I-Mutation vorliegt, oder<br>\\n<br>\\n-\\tPh+ chronischer myeloischer Leukämie (in der chronischen Phase, akzelerierten Phase oder Blastenkrise) oder Ph+ akuter Lymphoblastenleukämie, bei denen eine Behandlung mit anderen Inhibitoren der c-abl-Tyrosinkinase nicht geeignet ist.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2023-03-01\",\"validTo\":null}]",
  "galenic_form": "Filmtabl 45 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2023-03-01",
  "self_retention_pct": 10
}

See everything about ponatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.